

The imidazole residues exist in the N⁺-H tautomeric form* in which the non-protonated nitrogen (N⁺) is adjacent to the side chain. This differs from histamine base (as recrystallized from benzene) (Bonnet & Ibers, 1973) but is the same form as found in the crystal of L-histidine (Madden, McGandy, Seeman, Harding & Hoy, 1972; Madden, McGandy & Seeman, 1972), O-methyl-L-pyroglutamyl-L-histidine (Cotrait & Allard, 1973), 6-histaminopurine dihydrate (Thewalt & Bugg, 1972) and the H₂-receptor antagonists, burimamide (Kamenar, Prout & Ganellin, 1973) and N-methyl-N'-{2-(5-methylimidazol-4-yl)methylthioethyl}-thiourea (Critchley, S. R., Prout, K. & Ganellin, C. R. unpublished work).

The N⁺-H tautomer is generally regarded as being the biologically active (H₁-receptor) species of histamine and is the preferred form in aqueous solution, although, at 37°C the free-energy difference between the two tautomers is less than 1 kcal mol⁻¹ (Ganellin, 1973b).

We thank the Science Research Council for support (to S.R.C.) under the CASE (Co-operative Awards in Science and Engineering) scheme.

* Following the IUPAC-IUB Commission on Biochemical Nomenclature 1972 recommendations for histidine, the imidazole N nearer the side chain is designated N⁺, and the one farther is N⁺ (Black & Ganellin, 1974).

References

ASH, A. S. F. & SCHILD, H. O. (1966). *Brit. J. Pharmacol. Chemother.* **27**, 427-439.

BLACK, J. W., DUNCAN, W. A. M., DURANT, G. J., GANELLIN, C. R. & PARSONS, E. M. (1972). *Nature, Lond.* **236**, 385-390.

BLACK, J. W. & GANELLIN, C. R. (1974). *Experientia*, **30**, 111-113.

BONNET, J. J. & IBERS, J. A. (1973). *J. Amer. Chem. Soc.* **95**, 4829-4833.

BONNET, J. J. & JEANNIN, Y. (1972). *Acta Cryst.* **B28**, 1079-1085.

COTRAIT, M. & ALLARD, M. (1973). *C.R. Acad. Sci. Paris, Sér. C*, **276**, 1671-1674.

DECOU, D. F. JR (1964). Dissertation No. 64-9987, Univ. Microfilms Inc., Ann Arbor, Michigan.

GANELLIN, C. R. (1973a). *J. Med. Chem.* **16**, 620-623.

GANELLIN, C. R. (1973b). *J. Pharm. Pharmacol.* **25**, 787-792.

GANELLIN, C. R., PEPPER, E. S., PORT, G. N. J. & RICHARDS, W. G. (1973). *J. Med. Chem.* **16**, 610-616.

GANELLIN, C. R., PORT, G. N. J. & RICHARDS, W. G. (1973). *J. Med. Chem.* **16**, 616-620.

KAMENAR, B., PROUT, K. & GANELLIN, C. R. (1973). *J. Chem. Soc. Perkin*, pp. 1734-1738.

KIER, L. B. (1968). *J. Med. Chem.* **11**, 441-445.

MADDEN, J. C., MCGANDY, E. L. & SEEMAN, N. C. (1972). *B28*, 2377-2382.

MADDEN, J. J., MCGANDY, E. L., SEEMAN, N. C., HARDING, M. M. & HOY, A. (1972). *Acta Cryst.* **B28**, 2382-2389.

NORTH, A. C. T., PHILLIPS, D. C. & MATHEWS, F. S. (1968). *Acta Cryst.* **A24**, 351-359.

PYMAN, F. L. (1912). *J. Chem. Soc.* **101**, 530-544.

THEWALT, U. & BUGG, C. E. (1972). *Acta Cryst.* **B28**, 1767-1773.

VEIDIS, M. V., PALENIK, G. J., SCHAFFRIN, R. & TROTTER, J. (1969). *J. Chem. Soc. (A)*, pp. 2659-2666.

WATSON, H. C., SHOTTON, D. M., COX, J. M. & MUIRHEAD, H. (1970). *Nature, Lond.* **225**, 806-811.

YAMANE, T., ASHIDA, T. & KAKUDO, M. (1973). *Acta Cryst.* **B29**, 2884-2891.

Acta Cryst. (1974). **B30**, 2886

Jujubogenin *p*-Bromobenzoate

BY KEN-ICHI KAWAI,* YOICHI IITAKA AND SHOJI SHIBATA

Faculty of Pharmaceutical Sciences, University of Tokyo, Hongo, Tokyo 113, Japan

(Received 11 July 1974; accepted 26 July 1974)

Abstract. C₃₇H₅₁O₅Br.½AcOEt, m.p. 256-258°C, triclinic, space group *P*1, with *a* = 16.74 (1), *b* = 15.29 (1), *c* = 7.486 (5) Å, α = 94.25 (1), β = 102.00 (1), γ = 100.98 (1)°, *Z* = 2, *D*_x = 1.268 g cm⁻³, μ(Cu *K*α) = 22 cm⁻¹. The structure was solved by the heavy-atom anomalous dispersion method and refined to an *R* value of 0.076 for 1725 observed reflexions. The chemical structure of jujubogenin has been established

as 3β,20*S*-dihydroxy-16β(23*R*),16α(30)-dioxidodammar-24-ene. The dimensions and conformations of the two crystallographically independent molecules involved in the asymmetric unit generally agree with each other.

Introduction. Jujubogenin, C₃₀H₄₈O₄, is the main sapogenin obtained by periodate oxidation of jujuboside B isolated from *Zizyphus jujuba* Mill. and hovenoside G from *Hovenia dulcis* Thunb. (Kawai, Akiyama, Ogihara & Shibata, 1974). The *p*-bromobenzoate was recrystallized from ethyl acetate solution as colourless

* Present address: Hoshi College of Pharmacy, 2-4-41, Ebara, Shinagawa-ku, Tokyo 142, Japan.




Fig. 1. Bond lengths (Å), angles (°) and endocyclic torsion angles (°) averaged for the corresponding bonds in molecules I and I'.

References

- HALL, S. R. & MASLEN, E. N. (1965). *Acta Cryst.* **18**, 265–279.
International Tables for X-ray Crystallography (1962). Vol. III, pp. 202–207. Birmingham: Kynoch Press.
 KAWAI, K., AKIYAMA, T., OGIHARA, Y. & SHIBATA, S. (1974). *Phytochemistry*. In the press.

- KAWAI, K., IITAKA, Y., SHIBATA, S., KULSHRESHTHA, D. K. & RASTOGI, R. P. (1973). *Acta Cryst.* **B29**, 2947–2953.
 OKAYA, Y. & ASHIDA, T. (1967). *HBLV IV. The Universal Crystallographic Computing System* (I), p. 65. The Crystallographic Society of Japan.
 TANAKA, O., NAGAI, M., OHSAWA, T., TANAKA, N. & SHIBATA, S. (1967). *Tetrahedron Lett.* pp. 391–396.

Acta Cryst. (1974). **B30**, 2888

1-Methyl-3,3,5,5-tetraphenyl-1-thia-3,5-diphospha^v-2,6-diazin

VON JOHANNES WEISS

Anorganisch Chemisches Institut der Universität, Heidelberg, Deutschland (BRD)

(Eingegangen am 18. März 1974; angenommen am 18. Juli 1974)

Abstract. $C_{26}H_{24}N_2P_2S$, orthorhombic, *Pbnm*, $a=9.473$ (4), $b=11.551$ (5), $c=21.453$ (9) Å, $Z=4$, $D_c=1.30$ g cm^{-3} . The structure was refined by least-squares methods to $R=6.3\%$. The molecule has a mirror plane. The six-membered CN_2P_2S -ring is puckered. All bond lengths in the ring are between those of single and double bonds.

Einleitung. Appel & Hänssgen (1967) synthetisierten ein neues sechsgliedriges Ringsystem, das Kohlenstoff, Schwefel, Stickstoff und Phosphor als Ringglieder enthält. Von einem Vertreter dieser Gruppe, vom 1-Methyl-3,3,5,5-tetraphenyl-1-thia-3,6-diphospha^v-2,6-

diazin (I) wurde die Struktur röntgenographisch bestimmt.

